Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
This article will break down the specific dosages required to see a benefit, why this combination is so effective for your biology, and how to time your intake for maximum effect
Some peptides are studied for their interaction with growth hormone and IGF-1 pathways, which are associated with tissue repair and metabolic activity
They are often linked to oxidative stress and inflammation, which are caused by the accumulation of harmful molecules called free radicals in the body
No online checkout.
